"We are pleased to receive this patent from the USPTO, which ensures intellectual property protection for many years to come," said Shalabh Gupta, MD, Chief Executive Officer of Unicycive. "This Method of Use patent for UNI-494 is an important component of our strategy to become a leader in the development of drugs that target kidney disease. UNI-494 is currently in an ongoing Phase 1 clinical trial and recently received Orphan Drug Designation in Delayed Graft Function, a form of acute kidney injury. This ...

Patent and Intellectual Property - Unicycive Therapeutics received U S Patent No 12 036 211 for UNI-494, a compound targeting acute kidney injury and contrast-induced nephropathy, with protection valid until 2040 [1][2] - The patent covers a method of treating kidney-related conditions using UNI-494, without limitations on salt, dose, or administration type [2] - UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, addressing mitochondrial dysfunction in kidney diseases [2][4] Clinical Development and Strategy - UNI-494 is currently in a Phase 1 clinical trial in the UK, expected to complete in the second half of 2024 [4] - The compound has received Orphan Drug Designation from the FDA for Delayed Graft Function, a type of acute kidney injury [3][4] - The patent strengthens the company's strategy to lead in kidney disease drug development and expands its intellectual property portfolio [3] Market and Disease Context - Acute kidney injury (AKI) affects 20-200 per million population in the community, 7-18% of hospitalized patients, and approximately 50% of ICU patients [5] - AKI is associated with high morbidity and mortality, with an estimated 2 million deaths annually worldwide [5] - Delayed Graft Function, a form of AKI, occurs in the first week after kidney transplantation and is a key focus for UNI-494 [5] Company Overview - Unicycive Therapeutics is a biotechnology company focused on developing novel treatments for kidney diseases [6] - The company's lead drug candidate, oxylanthanum carbonate (OLC), targets hyperphosphatemia in chronic kidney disease patients on dialysis [6] - UNI-494 is a patent-protected new chemical entity in clinical development for acute kidney injury-related conditions [6]

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follo ...

LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024 at 2:00 p.m. ET. About Unicycive Therapeutics Investor Contact: SOURCE: Unicycive Therapeutics, Inc. A ...

– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the initial results from the patient reported outcome survey conducted during the UNI-OLC-201 pivotal clinical trial. The positive top-line results from the oxylanthanum carbonate (OLC) t ...

LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the initial results from the patient reported outcome survey conducted during the UNI-OLC-201 pivotal clinical trial. The positive top-line results from the oxylanthanum carbonate (OLC) trial in patients with hyperphosphatemia who have chronic kidney disease on dialysis we ...

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's US indexes serve as the benchmark for about $10.5 trillion in assets as of the close of December 2023. Russell indexes are part of FTSE Russell, a leading global index provider. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. For over 30 years, leading asset owners, asset managers, ETF p ...

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. "Inclusion in the Russell Microcap Index represents the latest mi ...

– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced positive results from the Oxylanthanum Carbonate (OLC) UNI-OLC-201 pivotal clinical t ...

– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury – LOS ALTOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that ...